Lysophosphatidylcholine Isoforms as Clinical Markers of Colorectal Cancer and Pol

溶血磷脂酰胆碱亚型作为结直肠癌和 Pol 的临床标志物

• 批准号: 7687117
• 负责人: WON KYOO CHO
• 金额: --
• 依托单位: RLR VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7687117
• 关键词: 3 year old; Adenomatous Polyps; Adherence; Affect; African American; Aging; Alcohol consumption; Biochemical; Biological Markers; Blood specimen; Cancer Etiology; Cancer Patient; Cancerous; Carcinoma; Caring; Cell physiology; Cessation of life; Clinic; Clinical Markers; Colon; Colonic Adenoma; Colonic Polyps; Colonoscopy; Colorectal; Colorectal Cancer; Data; Development; Diabetes Mellitus; Diagnosis; Diagnostic; Diagnostic Neoplasm Staging; Diet; Disease; Early Diagnosis; Elderly; Evaluation; Family history of; Fasting; Female; Gender; Goals; Healthcare; Incidence; Indiana; Inflammatory Bowel Diseases; Lesion; Link; Lipids; Lysophosphatidylcholines; Malignant - descriptor; Malignant Neoplasms; Medical; Medical center; Minority; Molecular; Operative Surgical Procedures; Patients; Pilot Projects; Plasma; Polyps; Population; Population Study; Premalignant; Preparation; Protein Isoforms; Race; Recording of previous events; Reporting; Reproducibility; Research; Risk Factors; Role; Sampling; Second Primary Cancers; Sensitivity and Specificity; Smoking; Staging; Survival Rate; Test Result; Testing; Time; United States; United States Department of Veterans Affairs; Universities; Veterans; Visit; Work; abstracting; adenoma; cancer diagnosis; cancer risk; case control; clinically significant; colorectal cancer screening; cost; demographics; follow-up; improved; male; minimally invasive; new therapeutic target; patient population; prognostic; public health relevance; tool

DESCRIPTION (provided by applicant): Project Summary/Abstract Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths in the United States. Since early detection of CRC is associated with excellent survival rates, development of non- invasive and highly reliable test for CRC is greatly needed for veterans. While colonoscopy has reported sensitivity and specificity values exceeding 95%, the degree of adherence is low due to the cost, as well as to perceived inconvenience and discomfort associated with this test. As a result, many patients still present with late-stage and potentially fatal disease. We have found that plasma levels of several lipids, called lysophosphatidylcholines (LPCs), are potential markers for CRC and our pilot work show that these markers achieved a sensitivity and specificity of 82% and 93%, respectively for CRC. It is critical and absolutely necessary to establish reproducibility and to retest and validate the estimates for sensitivity and specificity in completely independent VA population sets in order to critically evaluate the clinical significance and utility of these markers to be useful for veterans. We propose 2 aims. First, we will critically evaluate whether plasma LPC levels are effective markers for detecting CRC by determining their sensitivity and specificity in VA patient population, a totally independent study population. Secondly, we will determine whether plasma LPC levels are effective markers for pre-cancerous adenomatous colon polyps. Our long-term goals are 1) to develop highly sensitive and reliable diagnostic and prognostic, non- or minimally invasive biomarkers for improving early detection, management and follow up of CRC patient samples obtained and 2) to develop biomarkers to detect pre-cancerous adenomatous colon polyps. Potential Impact on Veterans Health Care: More veterans are diagnosed and/or treated for colorectal cancer in the Veteran Administration (VA) and such CRC incidence rate will increase with aging VA population. The proposed research will provide an important diagnostic non-invasive tool for veterans to improve early detection of CRC and colon polyp thus optimize CRC medical care for VA population. PUBLIC HEALTH RELEVANCE: Potential Impact on Veterans Health Care: More veterans are diagnosed and/or treated for colorectal cancer in the Veteran Administration (VA) and such CRC incidence rate will increase with aging VA population. The proposed research will provide an important diagnostic non-invasive tool for veterans to improve early detection of CRC and colon polyp thus optimize CRC medical care for VA population.

描述（由申请人提供）： 项目摘要/摘要结直肠癌（CRC）是美国第三大常见的癌症，是美国与癌症相关死亡的第二大原因。由于CRC的早期检测与优秀的生存率有关，因此对于退伍军人来说，非常需要对CRC进行非侵入性和高度可靠性测试。虽然结肠镜检查的敏感性和特异性值超过95％，但由于成本以及与此测试相关的不便和不适感，依从性程度很低。结果，许多患者仍然患有晚期和潜在致命疾病。我们发现，几种脂质的血浆水平（称为溶物磷脂酰胆碱（LPC））是CRC的潜在标记，我们的试点工作表明，这些标记的敏感性和特异性分别为82％和93％，分别为CRC。在完全独立的VA人群集中建立和重新测试和验证对敏感性和特异性的估计值以批判性评估这些标记的临床意义和效用是对退伍军人有用的，这是至关重要的，并且绝对必要。我们提出2个目标。首先，我们将批判性地评估血浆LPC水平是否通过确定VA患者人群的敏感性和特异性（一个完全独立的研究人群）是否是检测CRC的有效标记。其次，我们将确定血浆LPC水平是否是癌前腺瘤结肠息肉的有效标记。我们的长期目标是1）开发高度敏感且可靠的诊断和预后，非或微创生物标志物，以改善获得的CRC患者样本的早期检测，管理和随访以及2）以开发生物标志物以检测癌前腺瘤腺瘤性结肠息肉。对退伍军人卫生保健的潜在影响：在退伍军人管理（VA）中，诊断出更多的退伍军人和/或治疗了结直肠癌，而这种CRC的发病率将随着VA老龄化的增长而增加。拟议的研究将为退伍军人提供重要的诊断非侵入性工具，以改善对CRC和结肠息肉的早期发现，从而为VA人群优化CRC医疗服务。 公共卫生相关性： 对退伍军人卫生保健的潜在影响：在退伍军人管理（VA）中，诊断出更多的退伍军人和/或治疗了结直肠癌，而这种CRC的发病率将随着VA老龄化的增长而增加。拟议的研究将为退伍军人提供重要的诊断非侵入性工具，以改善对CRC和结肠息肉的早期发现，从而为VA人群优化CRC医疗服务。